On 2014 Jul 08, Swapnil Hiremath commented:

The POSEIDON trial was discussed on June 18th 2014 on the open online nephrology journal club, #NephJC, on twitter. Introductory comments are available at the NephJC website. It was a fascinating discussion, with participation from nephrologists, clinical pharmacologists, internists, and cardiologists. The conversation also touched upon other aspects of contrast-induced acute kidney injury. A transcript and three different curated (i.e. Storified) versions of the tweetchat are available at the same NephJC link.

On July 1st 2014, there was a video interview of principal investigator of the POSIEDON trial, Somjot Brar, which can be viewed on Youtube. Many important insights into the design and interpretation of the trial were provided by Dr Brar, and readers are encouraged to check out the video.

The highlights of the tweetchat and the hangout were:

1. The investigators should be commended for planning and executing this trial so meticulously. Also, the funding agency (Kaiser Permanente) for supporting this important trial.

2. The intervention (based on LVEDP measurement to guide fluid administration) was designed to identify patients in whom it would be safe to give higher volumes of saline.

3. This trial provides critical evidence that preventing contrast-induced acute kidney injury protects the patient from future negative, extra-renal adverse events, a finding that previously had been seen in observational and retrospective cohorts but had been absent from prospective trials.

Interested individuals can track and join in the conversation by following @NephJC or #NephJC, or visit the webpage at NephJC.com.

On 2014 Jul 08, Swapnil Hiremath commented:

The POSEIDON trial was discussed on June 18th 2014 on the open online nephrology journal club, #NephJC, on twitter. Introductory comments are available at the NephJC website. It was a fascinating discussion, with participation from nephrologists, clinical pharmacologists, internists, and cardiologists. The conversation also touched upon other aspects of contrast-induced acute kidney injury. A transcript and three different curated (i.e. Storified) versions of the tweetchat are available at the same NephJC link.

On July 1st 2014, there was a video interview of principal investigator of the POSIEDON trial, Somjot Brar, which can be viewed on Youtube. Many important insights into the design and interpretation of the trial were provided by Dr Brar, and readers are encouraged to check out the video.

The highlights of the tweetchat and the hangout were:

1. The investigators should be commended for planning and executing this trial so meticulously. Also, the funding agency (Kaiser Permanente) for supporting this important trial.

2. The intervention (based on LVEDP measurement to guide fluid administration) was designed to identify patients in whom it would be safe to give higher volumes of saline.

3. This trial provides critical evidence that preventing contrast-induced acute kidney injury protects the patient from future negative, extra-renal adverse events, a finding that previously had been seen in observational and retrospective cohorts but had been absent from prospective trials.

Interested individuals can track and join in the conversation by following @NephJC or #NephJC, or visit the webpage at NephJC.com.